Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride reduces DHT more effectively than finasteride.

Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.

There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.

Finasteride is effective for hair loss and may help prevent prostate cancer without increasing high-grade cancer risk.

Androgen levels can increase at any age, affecting symptoms like acne, hair loss, and prostate size.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

Finasteride lowers PSA levels and prostate size, requiring adjusted PSA interpretation for accurate cancer screening.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

Testosterone increases muscle mass regardless of DHT conversion blocking.

Urinary PSA could be an early marker for enlarged prostate.

Biofeedback treatment for dysfunctional voiding in adults showed no symptom improvement.

Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.

Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

Stopping finasteride improves sperm quality but not semen volume in young men.

There is no link between hair loss and prostate enlargement.

People with early-onset hair loss (AGA) have a higher risk of heart disease, metabolic syndrome, and prostate enlargement.

Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.

Large prostates link to more hair loss.

Finasteride reduces prostate size and symptoms with few side effects.

Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.

Finasteride treatment increased blood volume and reduced vessel leakiness in beagle prostates.

Large prostate patients more likely to have hair loss.

CEC levels may be a useful marker for predicting prostate cancer progression.

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

Cone beam computed tomography can allow for smaller safety margins around the target area in prostate cancer radiation treatment if used for ongoing treatment checks.

Obesity is linked to more severe lower urinary tract symptoms.

PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.

Combination therapy is more effective for prostate volumes over 60 ml.